17,261 trials
Various Advanced Cancer
Primary: Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs) — 3; 4; 3; 0 Participants
Diabetic Foot Ulcer · Diabetes Mellitus · Wounds
Primary: Number of Participants With Complete Ulcer Closure During the Treatment Period — 32; 4 Participants
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001
Fistulizing Crohn's Disease
Primary: Percentage of Participants Who Achieved Combined Fistula Response at Week 24 — 47.1; 29.2; 25.0 percentage of participants
Arteritis, Giant Cell
Primary: Adverse Events — 93 percentage of subjects
Head and Neck Cancer
Primary: Number of Participants With SAEs — 3 Number of Participants
COVID-19
Primary: Time-Weighted Average Daily Change From Day 1 in Viral Load in NP Swab Samples — -1.68; -2.25; -2.34; -2.24 log10 copies/mL — p=0.0004
Relapsed/Refractory Acute Myeloid Leukemia
Primary: Count of Patients With Treatment-Emergent Adverse Events (Phase 1) — 6 Participants
Covid19 · Anosmia · Fever
Primary: Number of Subjects With COVID-19 Symptoms at Day 3. — 93; 90; 9; 13 Participants — p=0.3849
Esophageal Cancer · Squamous Cell Esophagus Cancer · Adenocarcinoma Esophagus
Primary: Overall Response Rate (ORR) — 0.08 proportion of participant
Rheumatoid Arthritis
Primary: Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo — 18; 18; 14 Participants
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
Depressive Disorder · Anxiety
Primary: Double-blind Treatment Period: Change From Baseline in Hamilton Depression Rating Scale (HDRS17) Total Score at Week 6 (eITT Population) — -6.1; -6.5 Units on a scale…
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…